Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.
about
Novel therapeutic agents in the treatment of metastatic colorectal cancerNew therapeutic strategies for BRAF mutant colorectal cancersBRAF Mutation in Colorectal Cancer: An UpdateSimilar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistanceCombined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy.Beyond RAS and BRAF: a target rich disease that is ripe for pickingTechnological considerations for genome-guided diagnosis and management of cancerRAS and BRAF in metastatic colorectal cancer managementMechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancerAutophagy inhibition overcomes multiple mechanisms of resistance to BRAF inhibition in brain tumorsCombinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas.Genomic Profiling in Gastrointestinal Cancer: Are We Ready To Use These Data to Make Treatment Decisions?Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal CancerClinical responses to ERK inhibition in BRAFV600E-mutant colorectal cancer predicted using a computational model.Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma.High-throughput drug library screening identifies colchicine as a thyroid cancer inhibitorExtreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.A metastatic colon adenocarcinoma harboring BRAF V600E has a durable major response to dabrafenib/trametinib and chemotherapy.BRAF-Directed Therapy in Metastatic Colorectal Cancer.Precision medicine for advanced prostate cancer.Acquired resistance to combination treatment through loss of synergy with MEK and PI3K inhibitors in colorectal cancer.Pterostilbene Inhibits Human Multiple Myeloma Cells via ERK1/2 and JNK Pathway In Vitro and In Vivo.Important molecular genetic markers of colorectal cancer.LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancerTumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer.Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy.BRAF in metastatic colorectal cancer: the future starts now.Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer.The kinome 'at large' in cancer.The therapeutic potential of targeting the BRAF mutation in patients with colorectal cancer.Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma.Proteogenomic studies on cancer drug resistance: towards biomarker discovery and target identification.Molecular markers of prognosis and therapeutic targets in metastatic colorectal cancer.BRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment?Strategies for Overcoming Resistance in Tumours Harboring BRAF Mutations.Strategies for monitoring and combating resistance to combination kinase inhibitors for cancer therapy.
P2860
Q26769932-36216EC5-7318-447F-84DD-8CCE095F5A76Q26772277-B6DFECAF-B013-47A3-B7C6-BFA0FFA12F4DQ26781926-4E045D8B-1B1B-41BB-BE10-6E376A659939Q26795609-BD7EF334-407C-4E5E-AB4A-198FE609E592Q27853216-8B4BDAE2-6175-4A10-840E-9CC2EFB4AB08Q27853224-5880081E-35BB-4FE8-B108-A001DA5D1A5AQ27853371-F886C0B3-AEC7-42D6-A44B-0A03686FC9E7Q28066095-D2BC9447-355F-4798-A675-C318A6E4B3DCQ28066706-676F5EED-FDC5-424F-B021-69AE4ADA27E4Q28074175-67149CEF-D7DB-4EC1-B3F9-B4662D741374Q28076490-C3A9BF18-8C90-4640-8EDA-7A58EFC43039Q28468571-0B51AF98-21B2-49DF-826E-2158ADE717A9Q30277902-167EA466-E8F6-432F-9675-B3897AC47328Q31012680-BCE49CF7-5FEB-437C-B8BD-BD31B07B9D67Q33624491-8A420E48-EBAD-45EE-9298-41ACDF0FA1B7Q33767369-6ECC4543-2781-4744-BB5E-7D40042EC1B4Q35774120-23C8B551-3D7E-4BD9-BE66-D64727978627Q35945841-67E6B75B-4B3D-40BE-9907-BD08303B65B0Q36346641-859CFBFB-1867-4AE1-A271-D9BDAFA1BFE9Q36352341-36710E1D-A6C7-46D5-A85B-3216ADF4BAE3Q37041765-BD3BD9AF-DCDD-451B-B5FE-794E6008B136Q37114034-C43E76E3-0A23-476F-B445-A5AFD4B2CED0Q37301776-2F007CAF-B7AE-4AC5-823F-EED6A216028CQ37465698-CCB58213-5D86-455B-AD87-66AE3D4C5A12Q37619856-53121885-2D0E-4161-B2DB-362BCCDF69DFQ37705948-AB698E6C-5DD0-485E-AE22-F7BB0B354502Q38275060-45ABFE9A-D48F-49CF-A8F7-B6087548748AQ38630561-9130E83A-0E22-4144-8188-C0ADA00B8A58Q38652005-FDEE87D3-39B4-4AE4-BAE7-3E070C583670Q38706872-17DFCF61-EEC4-4B35-A9CF-DE4621D18F82Q38715428-1BF56704-0A66-418E-9AF7-A0CC7BEDD79AQ38730744-5A87E013-49FD-4204-B962-70A77784DC44Q38764035-58405A7A-A0E0-4291-BFE2-8EAD73969E8DQ38776411-4D685CEE-743D-49CA-9ED6-374DFF33305CQ38813507-C90D9EFA-B679-4A7C-8AF8-5477D3AD5A4FQ38918710-386232C3-807C-4A01-ADAA-7605A7284905Q38938329-551C7F92-46F7-4FB3-BDD9-44EDD07082C7Q38953687-F7A6896E-3575-40B6-9AA1-BC72E60271EAQ39173195-BDF38C0C-4C59-4019-BA88-F7A9395BD1D8Q39255218-CA628FCA-9027-4EBA-B8B1-FF22FA34DB8D
P2860
Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Clinical Acquired Resistance t ...... ough MAPK Pathway Alterations.
@en
type
label
Clinical Acquired Resistance t ...... ough MAPK Pathway Alterations.
@en
prefLabel
Clinical Acquired Resistance t ...... ough MAPK Pathway Alterations.
@en
P2093
P2860
P50
P1433
P1476
Clinical Acquired Resistance t ...... ough MAPK Pathway Alterations.
@en
P2093
A John Iafrate
Anuj Kalsy
Dora Dias-Santagata
Eliezer M Van Allen
Elizabeth L Lockerman
Erin M Sennott
Eunice L Kwak
Jason E Faris
Jason T Godfrey
Jeffrey A Engelman
P2860
P304
P356
10.1158/2159-8290.CD-14-1518
P577
2015-02-11T00:00:00Z